ROC Analysis for Phase II Group Sequential Basket Clinical Trial
DOI:
https://doi.org/10.6000/1929-6029.2017.06.01.3Keywords:
Basket trial, group sequential clinical trial, nonparametric ROC curve, parametric ROC curve, phase II clinical trial.Abstract
The basket trial is a recent development in the clinical trial practice. It conducts the test of the same treatment on several different related diseases in a single trial, and has the advantage of reduced cost and enhanced efficiency. A natural question is how to assess the performance of the group sequential basket trial against the classical group sequential trial? To our knowledge, a formal assessment hasn’t been seen in the literature, and is the goal of this study. Specifically, we use the receiver operating characteristic curve to assess the performance of the mentioned two trials. We considered two cases, parametric and nonparametric settings. The former is efficient when the parametric model is correctly specified, but can bemis-leading if the model is incorrect; the latter is less efficient but is robust in that it cannot be wrong no matter what the true data generating model is. Simulation studies are conducted to evaluate the experiments, and it suggests that the group sequential basket trial generally outperforms the group sequential trial in either the parametric and nonparametric cases, and that the nonparametric method gives more accurate evaluation than the parametric one for moderate to large sample sizes.
References
Willyard C. Basket studies?will hold intricate data for cancer drug approvals. Nature Medicine 2013; (6): 655. https://doi.org/10.1038/nm0613-655 DOI: https://doi.org/10.1038/nm0613-655
Redig AJ, Janne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. Journal of Clinical Oncology 2015; (20): 975-977. https://doi.org/10.1200/JCO.2014.59.8433 DOI: https://doi.org/10.1200/JCO.2014.59.8433
Beckman RA, Antonijevic Z, Kalamegham R, Chen C. Design for a phase 3 basket trial in multiple tumor types based on a putative biomarker. Clinical Cancer Research 2015; In press.
Chen C, Li N, Yuan S, Antonijevic Z, Kalamegham R, Beckman RA. Statistical design and consideration of a phase 3 basket trial for simultaneous investigation of multiple tumor types in one study 2016. DOI: https://doi.org/10.1080/19466315.2016.1193044
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology & Therapeutics 2009; 97-100. https://doi.org/10.1038/clpt.2009.68 DOI: https://doi.org/10.1038/clpt.2009.68
Kopetz S. Right Drug for the Right Patient: Hurdles and the path forward in colorectal cancer. ASCO educational book 2013. http://meetinglibrary.asco.org/content/19-132. DOI: https://doi.org/10.14694/EdBook_AM.2013.33.e115
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, et al.Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clinical Cancer Research 2014; 20: 2264-2275. DOI: https://doi.org/10.1158/1078-0432.CCR-13-1591
Lacombe D, Burocka S, Bogaertsa J, Schoeffskib P, Golfinopoulosa V, Stuppa R. The dream and reality of histology agnostic cancer clinical trials. Molecular Oncology 2014; 8: 1057-1063. DOI: https://doi.org/10.1016/j.molonc.2014.06.002
Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. Journal of Clinical Oncology 2013; 31: 1834-1841. DOI: https://doi.org/10.1200/JCO.2012.45.3639
Demetri G, Becker R, Woodcock J, Doroshow J, Nisen P, Sommer J. Alternative trial designs based on tumor genetics/pathway characteristics instead of histology. Issue Brief: Conference on Clinical Cancer Research; http://www.focr.org/ conference-clinical-cancer-research 2011.
Metz CE. Basic principles of ROC analysis. In Seminars in Nuclear Medicine 1978; (4): 283-298. WB Saunders. https://doi.org/10.1016/s0001-2998(78)80014-2 DOI: https://doi.org/10.1016/S0001-2998(78)80014-2
Zhou XH, Obuchowski AA, McClish DK. Statistical Methods in Diagnostic Medicine. 2011; Vol. 712: Wiley. com. https://doi.org/10.1002/9780470906514 DOI: https://doi.org/10.1002/9780470906514
Tang LL, Zhou XH. Semiparametric separation curve approach for comparing correlated ROC data from multiple markers, Journal of Computational and Graphical Statistics 2012; 662-676. https://doi.org/10.1080/10618600.2012.663303 DOI: https://doi.org/10.1080/10618600.2012.663303
Tang LL, Yuan A, Collins J, Che X, Chan L. Unified least squares methods for the evaluation of diagnostic tests with the gold standard 2016. DOI: https://doi.org/10.1177/1176935116686063
Pocock SJ. Group sequential methods in the design and analysis of clinical trials.Biometrika 1977; 191-199. https://doi.org/10.1093/biomet/64.2.191 DOI: https://doi.org/10.1093/biomet/64.2.191
O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 549-556. https://doi.org/10.2307/2530245 DOI: https://doi.org/10.2307/2530245
Berry DA. Interim analysis in clinical trials: Classical vs. Bayesian approaches. Statistics in Medicine 1985; 521-26. https://doi.org/10.1002/sim.4780040412 DOI: https://doi.org/10.1002/sim.4780040412
Wang SK, Tsaitis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987; 193-200. https://doi.org/10.2307/2531959 DOI: https://doi.org/10.2307/2531959
Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. The New England Journal of Medicine 1996; 1933-1940. https://doi.org/10.1056/NEJM199612263352601 DOI: https://doi.org/10.1056/NEJM199612263352601
Bellissant E, Duhamel JF, Guillot M, et al. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. Clinical Pharmacology and Therapeutics 1997; 377-384. https://doi.org/10.1016/S0009-9236(97)90170-3 DOI: https://doi.org/10.1016/S0009-9236(97)90170-3
Tan M, Xiong X, Kutner MH. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing. Biometrics 1998; 682-695. https://doi.org/10.2307/3109774 DOI: https://doi.org/10.2307/3109774
Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials, CRC Press Inc. (Boca Raton, FL) 2000. DOI: https://doi.org/10.1201/9780367805326
Hung J, Wang S-J, O’Neill R. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. Journal of Biopharmaceutical Statistics 2007; 1201-1210. https://doi.org/10.1080/10543400701645405 DOI: https://doi.org/10.1080/10543400701645405
Huang P, Tan MT. Multistage nonparametric global statistical test: a solution to the Behrens-Fisher problem for multidimensional mixed outcomes. Statistics and Its Interface 2016; 9(3): 343-354. DOI: https://doi.org/10.4310/SII.2016.v9.n3.a8
Qin J, Lawless JL. Empirical likelihood and general estimating equations. Annals of Statistics 1994; 22: 300-325. DOI: https://doi.org/10.1214/aos/1176325370
Owen AB. Empirical likelihood confidence regions. Annals of Statistics 1990; 18: 90-120. DOI: https://doi.org/10.1214/aos/1176347494
Yuan A, He W, Wang B, Qin G. U-statistic with side information. Journal of Multivariate Analysis 2012; 20-38. DOI: https://doi.org/10.1016/j.jmva.2012.04.008
Hyman DM,et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. New England Journal of Medicine 2015; 373: 726-736. DOI: https://doi.org/10.1056/NEJMoa1502309
Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAFV600E-positive papillary thyroid cancer: MD Anderson Cancer Center off label experience. The Journal of Clinical Endocrinology & Metabolism 2014; 100(1): E77-E81. DOI: https://doi.org/10.1210/jc.2014-2246
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Sirao Wang, Ao Yuan, Larry Tang, Hong Bin Fang, Ming T. Tan, Leighton Chan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
